Shots:
- The spin-off of the Diabetes Care business will allow the BD to strengthen its growth profile, enables it to focus on its other core businesses. The transaction is expected to be completed in H1’22
- Standalone Diabetes Care business is expected to leverage its position as a global leader in insulin delivery and expand its presence in the large and high-growth diabetes market. The spinoff allows both BD and NewCo to enhance each company’s focus on meeting the needs of their respective patients, customers, and stakeholders
- The BD’s diabetes care includes syringes, pen needles, and products for injecting insulin and other drugs
Click here to read full press release/ article | Ref: BD | Image: BD
The post BD to Spin Off its Diabetes Care Business into New Public Company first appeared on PharmaShots.
